Navigation Links
Rescuing Injured Hearts by Enhancing Regeneration

Using a two-drug approach, researchers at Children’s Hospital Boston have demonstrated that it may be possible to rescue heart function //after a heart attack and protect the heart from scarring. Working with rats, they combined an agent that overcomes a natural inhibitor of cell division with a naturally occurring growth factor that encourages blood vessel growth (angiogenesis). Together, these two agents enabled heart-muscle cells to multiply and the heart to regain its function after a simulated myocardial infarction.

Normally, after a heart attack, the damaged heart muscle cannot grow back and is instead replaced by scar tissue. Excessive scarring can impair the heart’s pumping capacity and can lead to life-threatening arrhythmias. Heart-muscle cells (cardiomyocytes) normally cannot replicate in mammals, a major obstacle to regeneration. However, in a paper last year, Felix Engel, PhD, and Mark Keating, MD, in the Department of Cardiology at Children’s Hospital Boston, showed that they could coax cardiomyocytes to multiply in a petri dish by inhibiting an enzyme known as p38 MAP kinase, which normally suppresses cardiomyocyte replication. [See: http://www.childrenshospital.org/newsroom
/Site1339/mainpageS1339P1sublevel139.html]

Engel and Keating (Keating is now at the Novartis Institute for BioMedical Research) now build on this finding. They studied 120 rats, some with simulated heart attacks. After the injury, the animals were randomly assigned to receive injections with a p38 MAP kinase inhibitor alone, the angiogenesis stimulator FGF1 alone, both agents together, or saline (placebo) for four weeks. Three months later, rats that had received both FGF1 and the p38 MAP kinase inhibitor had markedly improved heart function, as measured on echocardiograms: their hearts pumped almost as well as the hearts of uninjured rats. They also had reduced thinning of the cardiac wall and the least amount of scarring.

Rats receiving only the p38 MAP kinase inhibitor had increased proliferation of cardiomyocytes, but no longer had improved heart function at three months. Those receiving only FGF1 maintained their functional improvement, but did not show as much cell proliferation as those receiving the p38 MAP kinase inhibitor. Rats receiving both agents had the greatest improvements in both cell proliferation and heart function.

The findings suggest that getting cardiomyocytes to replicate is not enough to rescue heart function, but that angiogenesis is also needed, Engel says.

“Regeneration is not just making more cardiomyocytes,” he says. “Cardiomyocytes need a blood supply and oxygen to survive. FGF1 did not have a great effect on cell proliferation, but we found it was providing a new blood supply. If you just inhibit p38 MAP kinase, you don’t get blood vessels.”

Two important steps are needed to turn these findings into a treatment, Engel says. First is to show that the treatment works when not given immediately after the heart attack, since many people sustain progressive damage to their hearts from repeated minor infarctions. In this study, rats were treated soon after injury.

Second is the need to develop a safe delivery method. Because FGF1 stimulates angiogenesis, it has the potential for serious side effects if it goes to places other than the heart, possibly promoting tumor growth, for example. And the p38 MAP kinase inhibitor has been shown to damage the liver.

“Every treatment trying to induce proliferation of cardiomyocytes also carries a risk of inducing tumor growth, and thus you have to limit the time and location of treatment,” Engel adds.

One possibility is to inject smaller doses of the agents into the damaged area of the heart in gel form, or instill them through a catheter, so that they would remain in the heart and be released slowly over time. Engel and colleagues recently reported another compound that stimulates cardiomyocyte proliferation (Chemistry and Biology, Sept. 2006), and others are under investigation.

“In the end, we’d like a treatment that could be given systemically,” Engel says.

Source-Newwise
SRM
'"/>




Related medicine news :

1. Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision
2. Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision
3. Mobilizing Stem Cells at the Injured Site Using Hyperbaric Oxygen Treatments.
4. Guidelines For Treating Severely Injured Patients On The Anvil
5. Engineered Tissue Implants benefited Knee Injured patients
6. A Realistic Arm on the Anvil for Injured Soldiers
7. Vitamin E supports Female Hearts
8. Reconstituted Blood Better For Young Hearts
9. A Call To Open Up The Channel Of Goodwill To Rescue The Dying Hearts
10. Surgeons in India to Mend ‘Pakistani Hearts’ by treating 70 Childrn
11. Novel Biological Pacemaker Under Construction for Weak Hearts
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/10/2020)... ... January 10, 2020 , ... Sigma Theta Tau International Honor Society of Nursing ... Awards. These awards are regarded as one of the most important and prestigious designations ... of the Year competition has recognized Sigma for the last 11 consecutive years. , ...
(Date:1/10/2020)... ... ... The value of healthy vision can’t be overstated, and the most potent ... doctor, Brent Bellotte MD., champions such proactive care, advising that annual examinations are pivotal ... that many take for granted until a problem occurs. Eye disease is very common ...
(Date:1/8/2020)... ... January 08, 2020 , ... ... life sciences teams, announced today that the company is rebranding as Red Nucleus ... learning and performance solutions for the life sciences industry. , The addition ...
(Date:1/8/2020)... (PRWEB) , ... January 08, 2020 , ... Quality ... of providing a holistic care approach and to maintain a comfortable and preferred lifestyle ... Kavall has a passion for holistic care and has been a leader in the ...
(Date:1/7/2020)... ... January 07, 2020 , ... Destressing the patient payment and billing ... AI automation are among the topics to be examined at the HFMA Western Symposium, ... Fricano, chief executive officer for Healthfuse, a leader in supporting hospitals to more effectively ...
Breaking Medicine News(10 mins):
(Date:1/8/2020)... ... 09, 2020 , ... R3 Stem Cell, the nation's leader ... The cryogenic freezer allows practices to have plenty of stem cell and exosome ... require cryogenic freezing. This may include a practice receiving the biologics with overnight ...
(Date:1/7/2020)... ... 07, 2020 , ... China’s NMPA (CFDA):, Latest Regulatory Updates ... EST, https://www.fdanews.com/chinanpma , China is the second-largest medical device and in ... 20 percent annual growth rate year after year. , Stay up to speed ...
(Date:1/3/2020)... , ... January 03, 2020 , ... Stay on top ... medical device and food industries. Access to all webinars is free, so be sure ... in your field. , Visit http://www.xtalks.com to see our upcoming webinars: , ...
Breaking Medicine Technology: